elevated liver enzymes and semaglutide Once-Weekly Subcutaneous Improves Fatty Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study The weight-loss-independent hepatoprotective benefits of

Compounded medications are not themselves FDA-approved but are legal, regulated, and made to pharmaceutical standards for personalized patient use

The PIONEER 4 trial showed that oral semaglutide was noninferior to liraglutide (another GLP-1 receptor agonist) for HbA1c reduction but superior for weight loss, and superior to placebo for both outcomes

FDA requires black box warning

15 demonstrating powerful inhibition of food intake after ICV administration of GLP-1, an effect that could be blocked by the specific receptor antagonists exendin 939, which also enhanced spontaneous as well as neuropeptide Y-stimulated food intake

Shao S, Liu Y, Hong W, Mo Y, Shu F, Jiang L, et al